İ. DURSUN Et Al. , "Canakınumab Is Safe In The Treatment Of Renal Transplant Patıent Havıng AmyloıdosısSecondary To Hyper- Ig-D Syndrome," 23rd Paediatric Rheumatology European Society Congress , 2016
DURSUN, İ. Et Al. 2016. Canakınumab Is Safe In The Treatment Of Renal Transplant Patıent Havıng AmyloıdosısSecondary To Hyper- Ig-D Syndrome. 23rd Paediatric Rheumatology European Society Congress .
DURSUN, İ., SÖZERİ, B., PAÇ KISAARSLAN, A., DÜŞÜNSEL, R., & POYRAZOĞLU, M. H., (2016). Canakınumab Is Safe In The Treatment Of Renal Transplant Patıent Havıng AmyloıdosısSecondary To Hyper- Ig-D Syndrome . 23rd Paediatric Rheumatology European Society Congress
DURSUN, İSMAİL Et Al. "Canakınumab Is Safe In The Treatment Of Renal Transplant Patıent Havıng AmyloıdosısSecondary To Hyper- Ig-D Syndrome," 23rd Paediatric Rheumatology European Society Congress, 2016
DURSUN, İSMAİL Et Al. "Canakınumab Is Safe In The Treatment Of Renal Transplant Patıent Havıng AmyloıdosısSecondary To Hyper- Ig-D Syndrome." 23rd Paediatric Rheumatology European Society Congress , 2016
DURSUN, İ. Et Al. (2016) . "Canakınumab Is Safe In The Treatment Of Renal Transplant Patıent Havıng AmyloıdosısSecondary To Hyper- Ig-D Syndrome." 23rd Paediatric Rheumatology European Society Congress .
@conferencepaper{conferencepaper, author={İSMAİL DURSUN Et Al. }, title={Canakınumab Is Safe In The Treatment Of Renal Transplant Patıent Havıng AmyloıdosısSecondary To Hyper- Ig-D Syndrome}, congress name={23rd Paediatric Rheumatology European Society Congress}, city={}, country={}, year={2016}}